Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 2
2(50.0%)
4Total
N/A(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03279796Phase 2Unknown

Treatment of Tendon Disease Using Autologous Adipose-derived Mesenchymal Stem Cells

Role: collaborator

NCT03300531Phase 2Unknown

Impact of Autologous Pure Platelet-rich Plasma in the Treatment of Tendon Disease

Role: collaborator

NCT02487628Not ApplicableUnknown

Evaluation of HQ® Matrix Soft Tissue Mesh for the Treatment of Inguinal Hernia

Role: lead

NCT01993030Not ApplicableCompleted

Evaluation of HQ® Matrix Medical Wound Dressing for Healing of Donor Site Wounds

Role: lead

All 4 trials loaded